Glenmark Pharma Inks Deal With MeyerZall Labs (India)
This article was originally published in PharmAsia News
Glenmark Pharmaceuticals Ltd, one of India's biggest pharmaceutical companies, is teaming up with the South Africa-based MeyerZall Laboratories. The deal stretches for a period of 10 years. Over that time the two companies will work together to expand drugs in Glenmark's topical dermatology pipeline. These treatments will primarily focus on aiding patients suffering from psoriasis, fungal infections, and inflammation. Thanks to the new partnership, Glenmark and MeyerZall will be able to offer the largest range of topical dermatology products in South Africa. (Click here for more
You may also be interested in...
Amgen and Mylan will face US Food and Drug Administration actions dates on two of their biosimilar candidates in December, while ANDA sponsors have date-certain launches for two generic products.
With the European Commission "carefully assessing" the judgment of Europe's highest court that CBD is not a narcotic, HBW Insight speaks to an expert in cannabis law about what is likely to happen next.
The UK has used a special legislative process to temporarily authorize the use of the BNT-162b2 vaccine, with the first 800,000 shots expected to be delivered within days.